Acute exudative pancreatitis on CT scan. Credit: Hellerhoff.

Samsung Bioepis is set to start a Phase l trial to investigate SB26, also known as TAK-671, for the treatment of severe acute pancreatitis.

Pancreatitis is caused by the inflammation of the pancreas, a large organ behind the stomach that produces digestive enzymes and various hormones.

Samsung’s planned Phase l trial is a randomised, double-blind, placebo-controlled, single and multiple-dose escalation study that intends to evaluate the safety, tolerability and pharmacokinetics of intravenous SB26 in healthy subjects.

Results from the trial are expected to be available by the third quarter of 2020.

Samsung Bioepis senior vice-president and Clinical Sciences Division head Chul Kim said: “The upcoming clinical trial marks a major milestone for those of us at Samsung Bioepis, as SB26 is set to become the first novel biologic candidate from our company to enter clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Acute pancreatitis remains one of the most common gastrointestinal conditions, affecting more patients every year.”

“Acute pancreatitis remains one of the most common gastrointestinal conditions, affecting more patients every year.

“While mild acute pancreatitis is more easily treatable, severe acute pancreatitis, which affects approximately 20% of patients suffering from acute pancreatitis, can often be fatal. Unfortunately, treatment options remain extremely limited.”

SB26 is an ulinastatin-Fc (UTI-Fc) fusion protein developed to treat severe acute pancreatitis.

It has been developed under a risk-sharing strategic collaboration agreement between Samsung Bioepis and Takeda Pharmaceutical Company to jointly develop new biologic therapies.

SB26 combines Samsung Bioepis’ biologics development platform with Takeda’s expertise in drug development.